AHA26: Pelacarsen misses primary endpoint in Phase III HORIZON trial
At this year's American Heart Association (AHA) Scientific Sessions, primary results from the Phase III Lp(a) HORIZON trial evaluating Novartis'…
At this year's American Heart Association (AHA) Scientific Sessions, primary results from the Phase III Lp(a) HORIZON trial evaluating Novartis'…
Vasa Therapeutics has reported positive topline findings demonstrating clinical proof of concept for its lead therapy, VS-041, in a Phase…
A post hoc analysis of the Phase III ACHIEVE-3 trial shows that orforglipron 36mg delivered a greater reduction in predicted…
Boehringer Ingelheim’s dual-targeting weight-loss drug, survodutide, has shown safety with respect to cardiovascular events in a Phase III trial. In…
On 30 September, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan,…
On September 30, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan,…
This year at the European Association for the Study of Diabetes (EASD) Annual Meeting, real-world data compared cardiovascular outcomes with…
AstraZeneca’s oral relaxin agonist improved cardiac function in patients with chronic heart failure in a Phase IIb trial. In data…
This year at the European Society of Cardiology (ESC) Scientific Sessions, results from the Phase IV VICTORION-CHALLENGE trial provided the…
With the 2026 European Society of Cardiology (ESC) Congress in full swing, cardiologists and industry titans alike are gathering in…